Critical Analysis: InfuSystem (NYSE:INFU) vs. H-CYTE (OTCMKTS:HCYTD)

InfuSystem (NYSE:INFU) and H-CYTE (OTCMKTS:HCYTD) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, profitability, analyst recommendations, dividends, risk, valuation and institutional ownership.

Earnings & Valuation

This table compares InfuSystem and H-CYTE”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InfuSystem	$139.89 million	1.31	$870,000.00	$0.23	39.13
H-CYTE	$1.61 million	0.32	-$4.80 million	N/A	N/A

InfuSystem has higher revenue and earnings than H-CYTE.

Risk and Volatility

InfuSystem has a beta of 1.79, meaning that its stock price is 79% more volatile than the S&P 500. Comparatively, H-CYTE has a beta of 1.12, meaning that its stock price is 12% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings and target prices for InfuSystem and H-CYTE, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InfuSystem	0	1	1	3	3.40
H-CYTE	0	0	0	0	0.00

InfuSystem presently has a consensus price target of $13.50, indicating a potential upside of 50.00%. Given InfuSystem’s stronger consensus rating and higher probable upside, equities research analysts plainly believe InfuSystem is more favorable than H-CYTE.

Insider & Institutional Ownership

71.1% of InfuSystem shares are owned by institutional investors. 11.4% of InfuSystem shares are owned by company insiders. Comparatively, 5.2% of H-CYTE shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Profitability

This table compares InfuSystem and H-CYTE’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
InfuSystem	1.12%	2.78%	1.41%
H-CYTE	-450.40%	N/A	-777.68%

Summary

InfuSystem beats H-CYTE on 13 of the 13 factors compared between the two stocks.

About InfuSystem

InfuSystem Holdings, Inc., through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Patient Services and Device Solutions. It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states. The company also sells, rents, and leases new and pre-owned pole-mounted and ambulatory infusion pumps, and other durable medical equipment; sells treatment-related consumables; and provides biomedical recertification, maintenance, and repair services for oncology practices, as well as other healthcare site settings comprising hospitals, home care and home infusion providers, skilled nursing and acute care facilities, pain centers, and others. In addition, it offers local and field-based customer support, as well as operates pump service and repair centers. The company was incorporated in 2005 and is headquartered in Rochester Hills, Michigan.

About H-CYTE

H-CYTE, Inc., a biopharmaceutical company, develops and delivers various treatments for patients with chronic respiratory and pulmonary disorders in the United States. The company develops and implements treatment options in autologous cellular therapy to treat chronic lung disorders. It has a product supply agreement with Rion, LLC to develop and distribute a biologic for chronic obstructive pulmonary disease. The company is headquartered in Tampa, Florida.